Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

K. M. Bernot; R. F. Siebenaler; S. P. Whitman; N. A. Zorko; G. G. Marcucci; R. Santhanam; E. H. Ahmed; M. Ngangana; K. K. McConnell; J. S. Nemer; D. L. Brook; S. K. Kulp; C. S. Chen; D. Frankhouser; P. Yan; R. Bundschuh; X. Zhang; A. M. Dorrance; K. E. Dickerson; D. Jarjoura; W. Blum; G. Marcucci; M. A. Caligiuri

doi:10.1038/leu.2013.147

Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

K. M. Bernot, R. F. Siebenaler, S. P. Whitman, N. A. Zorko, G. G. Marcucci, R. Santhanam, E. H. Ahmed, M. Ngangana, K. K. McConnell, J. S. Nemer, D. L. Brook, S. K. Kulp, C. S. Chen, D. Frankhouser, P. Yan, R. Bundschuh, X. Zhang, A. M. Dorrance, K. E. Dickerson, D. JarjouraW. Blum, G. Marcucci, M. A. Caligiuri

Research output: Contribution to journal › Letter › peer-review

12 Scopus citations

Original language	English (US)
Pages (from-to)	2379-2382
Number of pages	4
Journal	Leukemia
Volume	27
Issue number	12
DOIs	https://doi.org/10.1038/leu.2013.147
State	Published - Dec 2013
Externally published	Yes

Bibliographical note

Funding Information:
We thank The Ohio State University Comprehensive Cancer Center’s Shared Resources: Biostatistics, Nucleic Acid, Comparative Pathology and Mouse Phenotyping and Analytical Cytometry. This work was supported in part by National Cancer Institute, Bethesda, MD, USA, grants: to MAC (CA089341; CA009338), to GM (CA102031), to MAC and GM (CA140158), to NAZ (T32 GM12453), and to KMB (T32 CA009338). We also thank the Thomas J. Bardos Science Education Award (RFS), the American Society of Hematology Trainee Research Award (RFS), the OSU College of Medicine Fellowship (NAZ), Pelotonia Fellowships (NAZ, RFS, and AMD), Wells Family Fellowship (JSN and DLB) and the American Society of Hematology Minority Medical Student Award Program (MN).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1038/leu.2013.147

OpenUrl availability

Full text

Cite this

Bernot, K. M., Siebenaler, R. F., Whitman, S. P., Zorko, N. A., Marcucci, G. G., Santhanam, R., Ahmed, E. H., Ngangana, M., McConnell, K. K., Nemer, J. S., Brook, D. L., Kulp, S. K., Chen, C. S., Frankhouser, D., Yan, P., Bundschuh, R., Zhang, X., Dorrance, A. M., Dickerson, K. E., ... Caligiuri, M. A. (2013). Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML. Leukemia, 27(12), 2379-2382. https://doi.org/10.1038/leu.2013.147

Bernot, KM, Siebenaler, RF, Whitman, SP, Zorko, NA, Marcucci, GG, Santhanam, R, Ahmed, EH, Ngangana, M, McConnell, KK, Nemer, JS, Brook, DL, Kulp, SK, Chen, CS, Frankhouser, D, Yan, P, Bundschuh, R, Zhang, X, Dorrance, AM, Dickerson, KE, Jarjoura, D, Blum, W, Marcucci, G & Caligiuri, MA 2013, 'Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML', Leukemia, vol. 27, no. 12, pp. 2379-2382. https://doi.org/10.1038/leu.2013.147

@article{618126f8362a4b5ba41a92dde3446fb5,

title = "Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML",

author = "Bernot, {K. M.} and Siebenaler, {R. F.} and Whitman, {S. P.} and Zorko, {N. A.} and Marcucci, {G. G.} and R. Santhanam and Ahmed, {E. H.} and M. Ngangana and McConnell, {K. K.} and Nemer, {J. S.} and Brook, {D. L.} and Kulp, {S. K.} and Chen, {C. S.} and D. Frankhouser and P. Yan and R. Bundschuh and X. Zhang and Dorrance, {A. M.} and Dickerson, {K. E.} and D. Jarjoura and W. Blum and G. Marcucci and Caligiuri, {M. A.}",

note = "Funding Information: We thank The Ohio State University Comprehensive Cancer Center{\textquoteright}s Shared Resources: Biostatistics, Nucleic Acid, Comparative Pathology and Mouse Phenotyping and Analytical Cytometry. This work was supported in part by National Cancer Institute, Bethesda, MD, USA, grants: to MAC (CA089341; CA009338), to GM (CA102031), to MAC and GM (CA140158), to NAZ (T32 GM12453), and to KMB (T32 CA009338). We also thank the Thomas J. Bardos Science Education Award (RFS), the American Society of Hematology Trainee Research Award (RFS), the OSU College of Medicine Fellowship (NAZ), Pelotonia Fellowships (NAZ, RFS, and AMD), Wells Family Fellowship (JSN and DLB) and the American Society of Hematology Minority Medical Student Award Program (MN).",

year = "2013",

month = dec,

doi = "10.1038/leu.2013.147",

language = "English (US)",

volume = "27",

pages = "2379--2382",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - Toward personalized therapy in AML

T2 - In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

AU - Bernot, K. M.

AU - Siebenaler, R. F.

AU - Whitman, S. P.

AU - Zorko, N. A.

AU - Marcucci, G. G.

AU - Santhanam, R.

AU - Ahmed, E. H.

AU - Ngangana, M.

AU - McConnell, K. K.

AU - Nemer, J. S.

AU - Brook, D. L.

AU - Kulp, S. K.

AU - Chen, C. S.

AU - Frankhouser, D.

AU - Yan, P.

AU - Bundschuh, R.

AU - Zhang, X.

AU - Dorrance, A. M.

AU - Dickerson, K. E.

AU - Jarjoura, D.

AU - Blum, W.

AU - Marcucci, G.

AU - Caligiuri, M. A.

N1 - Funding Information: We thank The Ohio State University Comprehensive Cancer Center’s Shared Resources: Biostatistics, Nucleic Acid, Comparative Pathology and Mouse Phenotyping and Analytical Cytometry. This work was supported in part by National Cancer Institute, Bethesda, MD, USA, grants: to MAC (CA089341; CA009338), to GM (CA102031), to MAC and GM (CA140158), to NAZ (T32 GM12453), and to KMB (T32 CA009338). We also thank the Thomas J. Bardos Science Education Award (RFS), the American Society of Hematology Trainee Research Award (RFS), the OSU College of Medicine Fellowship (NAZ), Pelotonia Fellowships (NAZ, RFS, and AMD), Wells Family Fellowship (JSN and DLB) and the American Society of Hematology Minority Medical Student Award Program (MN).

PY - 2013/12

Y1 - 2013/12

UR - http://www.scopus.com/inward/record.url?scp=84890437337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890437337&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.147

DO - 10.1038/leu.2013.147

M3 - Letter

C2 - 23660685

AN - SCOPUS:84890437337

SN - 0887-6924

VL - 27

SP - 2379

EP - 2382

JO - Leukemia

JF - Leukemia

IS - 12

ER -

Toward personalized therapy in AML: In vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML

Bibliographical note

UN SDGs

Access

OpenUrl availability

Other files and links

Cite this